Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885896 | 0.88 | GRIA1 (0.68) | GRIA1GRIA3PDE4DGRM5KDM4E | |
| SCHEMBL2953631 | 0.81 | GRIA1 (0.77) | GRIA1GRIA3PDE4DGRM5GABRA1 | |
| SCHEMBL1885015 | 0.80 | GRIA1 (0.66) | GRIA1GRIA3PDE4DGRM5KDM4E | |
| SCHEMBL1891395 | 0.78 | GRIA1 (0.62) | GRIA1GRIA3PDE4DGRM5 | |
| SCHEMBL1883493 | 0.77 | GRIA1 (0.60) | GRIA1GRIA3PDE4DGRM5GABRA1 | |
| SCHEMBL1882804 | 0.75 | GRIA1 (0.55) | GRIA1GRIA3PDE4D | |
| SCHEMBL1879971 | 0.74 | GRIA1 (0.57) | GRIA1GRIA3PDE4DGRM5KDM4E | |
| Perampanel SCHEMBL4214584 | 0.74 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5GABRA1 | |
| SCHEMBL1884996 | 0.74 | GRIA1 (0.79) | GRIA1GRIA3PDE4DGRM5GABRA1 | |
| Perampanel SCHEMBL194370 | 0.74 | GRIA1 (1.00) | GRIA1GRIA3PDE4DGRM5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | claimed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| EP-2254577-A1 | AMPA RECEPTOR ANTAGONISTS FOR EPILEPSY, MENTAL DISORDERS OR DEFICITS IN SENSORY ORGAN | Eisai R&D Management Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2008111590-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-18 | — | — | WO | disclosed |
| US-20060276510-A1 | Dihydropyridine compounds and compositions for headaches | EISAI CO. LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060270709-A1 | Dihydropyridine compounds and compositions for headaches | EISAI CO. LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | GRIA1 70/4885GRIA3 90/4885PDE4D 800/4885 |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | GRIK5, GABRE, GABRA5 | GRIA1 47/4885GRIA3 34/4885PDE4D 1445/4885 |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | CHRNA5, GRIN3A, CHRNA2 | GRIA1 70/4885GRIA3 60/4885PDE4D 1263/4885 |
| US-20060270709-A1 | Dihydropyridine compounds and compositions for headaches | GRIK5, CHRNA5, GRIN1 | GRIA1 38/4885GRIA3 63/4885PDE4D 554/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | AKR1B1, AKR1C1, AKR1C2 | GRIA1 24/4885GRIA3 56/4885PDE4D 2521/4885 |
| US-20060276510-A1 | Dihydropyridine compounds and compositions for headaches | QDPR, ACHE, HNMT | GRIA1 1702/4885GRIA3 1816/4885PDE4D 47/4885 |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | GRIK5, GRIK4, GRIK1 | GRIA1 34/4885GRIA3 31/4885PDE4D 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.